Dexamethasone or Dexamethasone in Combination With Thalidomide as Salvage Therapy

Completed · Phase 2

Conditions studied: Multiple Myeloma

In brief

The purpose of this investigational trial is to find out how well patients respond and how long their response lasts when treated with a standard regimen of dexamethasone with or without thalidomide and also find out what kind of side effects patients will experience.

Key facts

Study ID

NCT00083902

Run by

University of Arkansas

People needed

190

Starts

1998-06-01

Expected to finish

2005-05-01

Last updated by the study team

2010-07-02

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• All patients must have a confirmed diagnosis of previously treated, active multiple myeloma, with hypoproliferative/low risk relapse following at least one autologous transplant.
• Patients must be 18 years of age or older. Women of childbearing age and fertile men must use a medically acceptable means of birth control while on study and for 6 months thereafter.
• Patients must sign an informed consent to participate in this study, and be fully aware of the known teratogenic potential of this drug combination.
• Patients must have a SWOG performance status of 0-2.
• Patients must have adequate renal function, as defined by serum creatinine < or = 3.0 mg/dl.
• Patients must be off chemotherapy (including steroids) and local radiotherapy for > or equal 3 weeks prior to entering the study.

You may not qualify if…

• No other concurrent therapy for myeloma is permitted while on protocol.
• There must be no evidence of active infection requiring IV antibiotics.

Where it is running

• University of Arkansas for Medical Sciences/MIRT — Little Rock, Arkansas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.